CRTX
$49.73
Cortexyme
($.06)
(.12%)
CRTX
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.60)
Revenue:  $0.00 Mil
Monday
Nov 16
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CRTX reports earnings?
Beat
Meet
Miss

Where is CRTX's stock price going from here?
Up
Flat
Down
Stock chart of CRTX
Analysts
Summary of analysts' recommendations for CRTX
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Cortexyme Inc. is a clinical-stage biopharmaceutical company. It is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The company's drug candidate consists of COR388 which is in clinical stage. Cortexyme Inc. is based in San Francisco, United States.